Study of Ubamatamab Alone or With Cemiplimab in Adult Women With Recurrent Ovarian or MUC16-Positive Uterine Cancers
Led by Regeneron Pharmaceuticals · Updated on 2026-09-25
890
Participants Needed
54
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and dosing of ubamatamab alone or combined with cemiplimab in adult women with recurrent ovarian or uterine cancers that express MUC16. The study aims to understand how these drugs behave in the body, their potential to treat advanced recurrent ovarian or uterine cancer, and how pretreatment might help prevent Cytokine Release Syndrome CRS. This trial is a Phase 12 treatment study sponsored by Regeneron Pharmaceuticals.
Participants receive ubamatamab alone or together with cemiplimab according to the study protocol. The trial evaluates different doses and combinations to find the best regimen. The study also includes pretreatment to assess its safety and effectiveness in reducing CRS. Treatments are given sequentially in two experimental groups monotherapy with ubamatamab and combination therapy with ubamatamab plus cemiplimab.
During the study, participants undergo safety monitoring for dose-limiting toxicities, treatment-related adverse events, and serious events up to 2 years. Researchers measure drug levels in the blood and assess tumor responses using established cancer response criteria. Quality of life, physical function, and symptom scores are also tracked over time. The study collects data on immune response and long-term outcomes, with regular assessments throughout the treatment and follow-up periods.
CONDITIONS
Brief Title
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Ubamatamab Alone or Combined With Cemiplimab
Current Standard Therapy (Chemotherapy, Targeted, Immunotherapy)
What it is
A novel bispecific antibody (ubamatamab) targeting MUC16 and CD3, administered alone or with cemiplimab in patients with recurrent ovarian and related cancers.
Established systemic therapy options for recurrent ovarian, fallopian tube, peritoneal, or endometrial cancer after platinum therapy, including chemotherapy (e.g., carboplatin, paclitaxel), PARP inhibitors, bevacizumab, and immunotherapy as recommended by clinical guidelines.
Primary use
Investigational therapy intended to assess safety, tolerability, and anti-tumor activity in patients with recurrent or progressive MUC16-expressing cancers who lack effective standard therapy.
Standard therapies aim to control disease progression, improve survival, and manage symptoms in patients with recurrent ovarian or endometrial cancers following previous platinum-based treatments.
Evidence status
Early-stage clinical trial; no published results for efficacy or patient outcomes as of latest registry and translational publication.
Therapies have demonstrated efficacy and safety in recurrent cancer patients through multiple randomized trials and guideline-based evidence.
Important limitations
As an early-stage investigational therapy, ubamatamab’s clinical benefit, safety, risks, and optimal dosing remain unknown until results are posted from this ongoing study.
Standard therapies may be limited by cumulative toxicity, resistance, and declining response rates with increasing prior lines of treatment, as noted in guidelines.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
FEMALE
Eligibility Criteria
You may qualify if you...
Female patients with confirmed advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer with serum CA-125 2 times upper limit of normal (except low-grade serous carcinoma)
Patients must have received at least one line of platinum-containing therapy or be platinum-intolerant
Documented relapse or progression after most recent therapy
No standard therapy options likely to provide clinical benefit
Adequate organ and bone marrow function as specified
Life expectancy of at least 3 months
For randomized phase 2 expansion: platinum-resistant ovarian cancer patients with 2 to 4 prior platinum-based therapies
Patients with endometrial cancer that progressed or recurred after prior anti-PD-1 therapy and platinum chemotherapy
Tumor cells must show 25% MUC16 positivity by immunohistochemistry
1 to 4 prior lines of systemic therapy for endometrial cancer
You will not qualify if you...
Prior treatment with anti-PD-1 or anti-PD-L1 therapy as defined
For ovarian cancer expansion cohorts: more than 4 prior lines of cytotoxic chemotherapy (except low-grade serous ovarian cancer)
Prior treatment with MUC16-targeted therapy
Untreated or active primary brain tumor, CNS metastases, or spinal cord compression
History or current cardiovascular disease as defined
Severe or uncontrolled hypertension at screening; patients on antihypertensives must have stable regimen
Other protocol-defined exclusion criteria apply
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 2 years
Participants receive ubamatamab alone or in combination with cemiplimab according to the study protocol to evaluate safety, dosing, and treatment effects.
Follow-up
Duration - Up to 2 years
Participants are monitored for adverse events, tumor response, and quality of life during and up to 2 years after treatment.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Safety and Dosimetry Study of 177Lu-RAD204 Targeting PD-L1 in Patients With Selected Metastatic Solid Tumors
Study of 177LuBetaBart Monoclonal Antibody for Safety and Early Effects in Adults With Advanced Solid Tumors
Evaluating 18F-T2 PETCT Imaging for Detecting Tumors with High CAIX Levels in Adults
Study of Using 3D-Printed Custom Devices for High-Dose Radiation Treatment in Gynaecological Cancer
Phase II Study of SYS6041 Combination Therapy Evaluating Safety and Efficacy in Recurrent Ovarian Cancer
Phase III Trial Comparing BNT323 Versus Chemotherapy for HER2-Positive Recurrent Endometrial Cancer
Study on Cervical and Endometrial Cancer in Women Aged 20 to 75
Open-Label Phase 1 Trial Evaluating Safety and Activity of HH160 Alone or With Other Cancer Treatments in Adults With Advanced or Metastatic Solid Tumors
Study of CTIM-76, a Claudin-6 Directed Bispecific Antibody, in Adults With Platinum-Resistant Ovarian Cancer and Advanced Solid Tumors
Phase 1 Open-label Study of LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, Given Intravenously in Advanced Solid Tumors to Determine Safety and Recommended Dose
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer.